Ensign Peak Advisors
WST icon

Ensign Peak Advisors’s West Pharmaceutical WST Stock Holding History

Ensign Peak Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
29,576
+1,167
+4% +$357K 0.02% 426
2026
Q1 		$7.12M Sell
28,409
-61,328
-68% -$15.3M 0.01% 471
2025
Q4 		$24.7M Sell
89,737
-13,785
-13% -$3.77M 0.04% 266
2025
Q3 		$27.2M Buy
103,522
+9,946
+11% +$2.42M 0.04% 271
2025
Q2 		$20.5M Sell
93,576
-14,994
-14% -$3.21M 0.04% 312
2025
Q1 		$24.3M Sell
108,570
-35,237
-25% -$9.71M 0.05% 277
2024
Q4 		$47.1M Sell
143,807
-18,844
-12% -$5.93M 0.08% 197
2024
Q3 		$48.8M Sell
162,651
-2,094
-1% -$641K 0.09% 188
2024
Q2 		$54.3M Sell
164,745
-68,023
-29% -$24M 0.1% 174
2024
Q1 		$92.1M Buy
232,768
+97,147
+72% +$35.9M 0.17% 120
2023
Q4 		$47.8M Buy
135,621
+23,496
+21% +$8.32M 0.09% 192
2023
Q3 		$42.1M Sell
112,125
-43,690
-28% -$16.9M 0.09% 185
2023
Q2 		$59.6M Sell
155,815
-3,379
-2% -$1.21M 0.12% 151
2023
Q1 		$55.2M Sell
159,194
-32,074
-17% -$9.37M 0.12% 161
2022
Q4 		$45M Buy
191,268
+67,489
+55% +$16M 0.1% 181
2022
Q3 		$30.5M Buy
123,779
+30,489
+33% +$9.29M 0.08% 216
2022
Q2 		$28.2M Buy
93,290
+60,511
+185% +$19.7M 0.07% 227
2022
Q1 		$13.5M Buy
32,779
+1,602
+5% +$627K 0.03% 364
2021
Q4 		$14.6M Buy
31,177
+13,283
+74% +$5.72M 0.03% 383
2021
Q3 		$7.6M Sell
17,894
-2,213
-11% -$933K 0.02% 506
2021
Q2 		$7.22M Sell
20,107
-1,380
-6% -$456K 0.01% 522
2021
Q1 		$6.05M Sell
21,487
-469
-2% -$134K 0.01% 559
2020
Q4 		$6.22M Buy
21,956
+594
+3% +$167K 0.01% 539
2020
Q3 		$5.87M Buy
21,362
+14,212
+199% +$3.76M 0.01% 578
2020
Q2 		$1.62M Sell
7,150
-51,507
-88% -$10.1M ﹤0.01% 1082
2020
Q1 		$8.93M Hold
58,657
– – 0.03% 376
2019
Q4 		$8.82M Buy
+58,657
New +$8.54M 0.02% 482

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ensign Peak Advisors's WST Position: Q2 2026 in Review

Ensign Peak Advisors increased its West Pharmaceutical (WST) stake by 4.1% in Q2 2026, buying an estimated $357K and bringing the position to 29,576 shares worth $10.6M. The position accounts for 0.02% of the portfolio, ranked #426.

Ensign Peak Advisors first reported a position in WST in Q4 2019 and has held it in 27 quarters since. The position peaked at $92.1M in Q1 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Ensign Peak Advisors held 29,576 shares of West Pharmaceutical worth $10.6M as of Q2 2026.
  • Ensign Peak Advisors bought 1,167 West Pharmaceutical shares in Q2 2026, an estimated $357K.
  • West Pharmaceutical made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #426 holding.
  • Ensign Peak Advisors first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's West Pharmaceutical position peaked at $92.1M in Q1 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.